Delivery Order SPE2DB25D7060-SPE2DB25FXSSS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packages (30 count). This competitive award, valued at $4,145.28 with firm fixed pricing, is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation and represents a routine pharmaceutical procurement supporting...
- This delivery order, awarded on August 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $1,742.70 under firm fixed price terms. The contract is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $3,631.02 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) on August 11, 2025, with completion due by August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger prime indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,476.51 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with an ultimate completion date of September 10, 2025. This competitive award, issued on September 9, 2025, utilizes firm fixed pricing with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $1,108.80 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30 count). This competitively awarded, firm fixed-price contract has an ultimate completion date of August 29, 2025, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition in the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of MICARDIS HCT 80-25 mg tablets in unit dose packaging (30-count packages) with a ceiling value of $17,061.44. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is set for completion by August 18, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. MICARDIS HCT is a combination...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $2,508.25. This competitive, non-set-aside award utilizes firm fixed price pricing and carries an ultimate completion date of September 4, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,493.15, is for the delivery of Micardis HCT 40-12.5 mg tablets. The delivery order has an ultimate completion date of June 23, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,772.81 to AmerisourceBergen Drug Corp for Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a completion deadline of September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DB25D7060Indefinite Delivery Contract
- SPE2DB25D7060-SPE2DB25FXSSSDelivery Order
This delivery order, awarded on August 27, 2025, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) with a ceiling value of $9,314.20. The contract utilizes firm fixed pricing with an ultimate completion date of August 28, 2025, and was competitively awarded by the Defense Logistics Agency without any set-aside designation. This delivery order functions as a child contract under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The Defense Logistics Agency procures this medication to support military healthcare requirements and the Defense Health Agency's medical supply chain operations. AmerisourceBergen's extensive federal contracting portfolio demonstrates its role as a critical vendor for pharmaceutical procurement across multiple therapeutic domains, including cardiovascular medications like Micardis HCT. The company's ability to maintain multiple competitive awards reflects its capacity to fulfill federal medical supply needs efficiently. The DLA is currently planning the establishment of Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards anticipated, positioning strategic vendors like AmerisourceBergen to continue serving military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 8/27/25 |